세계의 항감염제 시장 규모 : 약제 유형별, 적응증별, 유통 채널별, 지역 범위별 및 예측
Global Anti Infective Drugs Market Size By Drug Type (Antibiotics, Antivirals), By Indication (HIV, Pneumonia, Respiratory Infections), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Geographic Scope And Forecast
상품코드:1732130
리서치사:Verified Market Research
발행일:2025년 04월
페이지 정보:영문 202 Pages
라이선스 & 가격 (부가세 별도)
한글목차
항감염제 시장 규모와 예측
항감염제 시장 규모는 2024년에 1,387억 7,000만 달러로 평가되며, 2026-2032년에 CAGR 5.05%로 성장하며, 2032년에는 2,058억 1,000만 달러에 달할 것으로 예측됩니다.
시장 확대에 박차를 가하고 있는 중요한 요소는 독감 유행 증가입니다. 전염성 바이러스인 독감은 경증에서 중등도의 증상뿐만 아니라 사망을 포함한 심각한 합병증을 유발할 수 있습니다. 이 보고서는 세계 항감염증 치료제 시장을 종합적으로 평가한 보고서입니다. 이 보고서는 다양한 부문과 시장에서 중요한 역할을 하는 동향 및 요인에 대한 분석으로 구성되어 있습니다.
세계 항감염증 치료제 시장의 정의
세계보건기구(WHO)가 인식하고 있는 세계 건강 부담의 주요 원인 중 하나는 감염성 질환입니다. 감염성 질환은 세균 감염, 진균 감염증, 바이러스 감염 등 다양한 병원체에 의해 유발되는 치명적인 질병입니다. 항감염제는 여러 원인에 의해 발생하는 감염증을 치료하기 위해 일반적으로 사용되는 치료법입니다. 항감염제는 감염을 일으키는 생물을 제거하거나 다양한 독소를 방출하여 숙주의 복제 및 감염을 막는 데 사용됩니다.
감염증을 일으키는 미생물에는 세균, 바이러스, 진균, 곰팡이, 바이러스, 미세 기생충 등이 있습니다. 감염성 질환은 원인 미생물의 유형과 환자의 질병 징후와 증상에 따라 분류됩니다. 오늘날 지구 전체가 직면하고 있는 가장 심각한 건강 문제 중 하나는 감염성 질환입니다. 전염병은 세균 감염, 진균 감염증, 바이러스 감염 등 많은 병원균에 의해 발생하는 치명적인 질병입니다. 감염은 빠르게 확산되며 항감염제는 곰팡이, 박테리아, 바이러스 및 기타 병원균을 포함한 다양한 미생물 종을 치료하는 데 사용됩니다.
항감염제는 다양한 원인에 의해 발생하는 감염증을 치료하기 위해 일반적으로 사용되는 치료법입니다. 항감염제는 DNA 생성을 억제하거나 세포 성분을 파괴하여 감염 확산을 막는 등 여러 가지 방식으로 작용합니다. 항감염제 시장에는 미생물 질환을 치료하기 위한 브랜드 또는 제네릭 항감염제, 그리고 관련 제품 및 서비스를 제조하는 사업체(조직, 개인 사업자, 파트너십)가 참여하고 있습니다.
세계 항감염제 시장 개요
인간면역결핍바이러스(HIV)의 면역체계 손상으로 인해 인간은 점점 더 감염에 취약해지고 있으며, HIV를 적시에 치료하지 않으면 후천성면역결핍증후군(AIDS)이 발병할 수 있습니다. 유엔에이즈계획(UNAIDS)에 따르면 2020년에만 전 세계에서 약 150만 명이 HIV에 감염되어 있으며, HIV는 백혈구로 알려진 CD4 세포에 해를 끼쳐서 죽게 만듭니다. 이는 질병과 싸우는 신체의 능력을 방해합니다. 항바이러스제는 바이러스의 증식을 막고 체내 HIV 수치를 낮추며 면역체계의 세포 생산을 다시 활성화합니다. 시장 확대에 박차를 가하는 또 다른 중요한 요소는 독감 유행 증가입니다. 전염성 바이러스인 독감은 경증에서 중등도의 증상뿐만 아니라 사망을 포함한 심각한 합병증을 유발할 수 있습니다.
질병통제예방센터(CDC)는 2018-2019년 3,550만 명이 독감에 걸려 49,600명이 입원하고 34,200명이 사망했다고 보고하면서 항감염증 치료제 산업의 성장에 힘을 실어주고 있습니다. 항감염증 치료제 시장은 골수 및 장기 칩(OOC) 기술 등 최근 신약 개발 방법의 발전으로 수혜를 받을 것으로 예상되며, OOC는 장기 시스템의 운동, 움직임, 생리적 반응을 재현하기 위해 정교하게 구축된 생체인식 시스템입니다. 표적의 식별, 검증, 스크리닝은 OOC와 줄기세포 기술을 이용한 임상시험 절차의 한 예입니다. 이러한 기술은 의약품 개발 비용을 절감하고, 의약품의 효능과 인체 안전성에 대한 신뢰할 수 있는 예측을 제공합니다.
그러나 시장 개발은 높은 연구개발비용과 의료 시설의 자원 부족으로 인해 제약이 있을 수 있습니다. 그러나 세계보건기구(WHO)는 2030년까지 6명 중 1명이 60세 이상이 될 것이며, 2050년까지 전 세계 60세 이상 인구는 21억 명으로 두 배로 증가할 것으로 예측하고 있으며, 80세 이상 인구는 2020-2050년 사이에 3배 증가하여 4억 2,600만 명에 달할 것으로 예상하고 있습니다. 증가할 것으로 예측됩니다. 노화에 따른 면역체계의 저하로 인해 질병과 싸우고 예방접종에 반응하는 신체의 능력이 저하됩니다. 면역계는 자가 병원체와 외래 병원체를 구별하는 능력이 저하됩니다. 과거에 만난 항원에 대한 기억을 가지고 있는 T세포는 새로운 항원에 대한 반응이 둔해집니다. 동반질환 증가와 면역체계의 활동성 저하로 인해 사람들은 감염에 더 취약해지며, 이는 시장 성장을 촉진하고 있습니다.
목차
제1장 세계의 항감염제 시장의 도입
시장의 정의
시장 세분화
조사 스케줄
전제조건
제한 사항
제2장 VERIFIED MARKET RESEARCH의 조사 방법
데이터 마이닝
데이터 삼각측량
보텀업 어프로치
톱다운 어프로치
조사 흐름
업계 전문가에 의한 주요 인사이트
데이터 소스
제3장 개요
시장 개요
에콜로지 매핑
절대적 매출 기회
시장의 매력
세계의 항감염제 시장 지역별 분석(CAGR %)
세계의 항감염제 시장 : 약제 유형별
세계의 항감염제 시장 : 적응증별
세계의 항감염제 시장 : 유통 채널별
향후 시장 기회
세계 시장 분할
제품 라이프 라인
제4장 세계의 항감염제 시장 전망
세계의 항감염제의 진화
촉진요인
촉진요인 1
촉진요인 2
억제요인
억제요인 1
억제요인 2
기회
기회 1
기회 2
Porter's Five Forces 모델
밸류체인 분석
가격 분석
거시경제 분석
세계의 항감염제 시장, 약제 유형별
개요
항생제
항바이러스제
항진균제
제5장 세계의 항감염제 시장 : 적응증별
개요
HIV
폐렴
호흡기 감염증
결핵
기타
제6장 세계의 항감염제 시장 : 유통 채널별
개요
병원 약국
소매 약국
기타
제7장 세계의 항감염제 시장 : 지역별
개요
북미
미국
캐나다
멕시코
유럽
독일
영국
프랑스
이탈리아
스페인
기타 유럽
아시아태평양
중국
일본
인도
기타 아시아태평양
라틴아메리카
브라질
아르헨티나
기타 라틴아메리카
중동 및 아프리카
아랍에미리트
사우디아라비아
남아프리카공화국
기타 중동 및 아프리카
제8장 세계의 항감염제 시장의 경쟁 구도
개요
각사의 시장 순위
주요 발전
기업의 지역별 발자국
기업의 산업별 발자국
ACE 매트릭스
제9장 기업 개요
Novartis AG
Merck & Co., Inc
Alcon Pharmaceuticals Ltd
Quest Diagnostics Inc.
AstraZeneca Plc
Anofi SA
GSK
Gilead Sciences
Novartis AG
Cipla
제10장 VERIFIED MARKET INTELLIGENCE
VERIFIED MARKET INTELLIGENCE 소개
역동적인 데이터 시각화
KSA
영문 목차
영문목차
Anti Infective Drugs Market Size And Forecast
Anti Infective Drugs Market size was valued at USD 138.77 Billion in 2024 and is projected to reach USD 205.81 Billion by 2032, growing at a CAGR of 5.05% from 2026 to 2032
An important element fueling the market's expansion is the rise in the prevalence of influenza. A contagious virus, influenza can result in both mild to moderate symptoms and serious complications, including death. The Global Anti Infective Drugs Market report provides a holistic evaluation of the market. The report comprises various segments as well as an analysis of the trends and factors that are playing a substantial role in the market.
Global Anti Infective Drugs Market Definition
One of the major global health burdens recognised by the World Health Organisation (WHO) is infectious illnesses. It is a potentially lethal illness brought on by a number of pathogens, such as bacterial, fungal, and viral infections. Anti-infectives are a form of therapy commonly used to treat infections brought on by a number of causes. Anti-infective drugs are used to eliminate infection-causing organisms or stop them from replicating or infecting the host by releasing a variety of toxins.
Microorganisms that cause infections include bacteria, viruses, fungi, viruses, and microparasites. Infections are categorised according to the type of organism that causes them as well as the patient's signs and symptoms of illness. One of the most significant health issues facing the entire globe today is infectious diseases. It is a potentially lethal illness brought on by a number of pathogens, including bacterial, fungal, and viral infections. Infectious diseases spread swiftly, and anti-infective drugs are used to treat a wide variety of microbiological species, including fungi, bacteria, viruses, and other pathogens.
Anti-infectives are a form of therapy commonly used to treat infections brought on by a number of causes. Anti-infective drugs function in several ways, such as by blocking DNA production and/or by destroying the cellular component to stop the infection from spreading. The Anti Infective Drugs Market is populated by entities (organisations, sole traders, and partnerships) that produce branded or generic anti-infective pharmaceuticals to treat microbial illnesses as well as related products and services.
Global Anti Infective Drugs Market Overview
Humans are increasingly becoming susceptible to infections as a result of the human immunodeficiency virus (HIV), which damages the immune system. If HIV is not treated in a timely manner, Acquired Immunodeficiency Syndrome (AIDS) may manifest. Around 1.5 million people worldwide contracted HIV in 2020 alone, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS). HIV causes harm to or kills CD4 cells, often known as white blood cells. This interferes with the body's ability to fight disease. Antiviral medications prevent the virus from multiplying, lowering the body's level of HIV and reactivating the immune system's cell production. Another important element fueling the market's expansion is the rise in the prevalence of influenza. A contagious virus, influenza can result in both mild to moderate symptoms and serious complications, including death.
The expansion of the anti-infective drugs industry was boosted by the 35.5 million people who contracted influenza in 2018-2019, the Centres for Disease Control and Prevention (CDC) reports, which led to 490,600 hospitalisations and 34,200 fatalities. The Anti Infective Drugs Market is expected to benefit from recent advances in drug discovery methods, such as bone marrow and organ-on-chip (OOC) technology. OOCs are biometric systems that have been meticulously built to replicate the motions, movements, and physiological responses of organ systems. Target identification, validation, and screening are examples of clinical trial procedures that use OOC and stem cell technologies. These technologies are reducing the expenses associated with drug development and provide reliable predictions of medicinal efficacy and human safety.
Market expansion, however, can be constrained by high research and development costs as well as a lack of resources in healthcare facilities. However, The World Health Organisation (WHO) predicts that by 2030, one in every six people will be 60 years of age or older and that by 2050, the number of people in the world who are 60 years of age or older will have doubled (to 2.1 billion). The number of people 80 and older is expected to treble between 2020 and 2050, reaching 426 million. Age-related immune system deterioration renders the body's capacity to fight disease and respond to immunisations less effective. The immune system becomes less adept at telling self-agents apart from alien ones. T cells that retain memories of previously met antigens react less quickly to novel antigens. Due to an increase in comorbid disorders and a decline in immune system activity, people are more susceptible to infections, which is what is causing the market to grow.
Global Anti Infective Drugs Market Segmentation Analysis
The Global Anti Infective Drugs Market is segmented on the basis of Drug Type, Indication, Distribution Channel, And Geography.
Anti Infective Drugs Market, By Drug Type
Antibiotics
Antivirals
Antifungals
Based on Drug Type, the market is segmented into Antibiotics, Antivirals, and Antifungals. Anti-infective medications known as antibiotics are used to treat bacterial infections. They function by either eradicating the germs or preventing them from proliferating, allowing the body's immune system to successfully combat the infection. A variety of bacterial illnesses, including those of the respiratory system, skin, urinary tract, and ears, are frequently treated with antibiotics. They come in a variety of forms, including tablets, capsules, injections, creams, and ointments.
A class of anti-infective medication known as antiviral is used to treat viral infections. They function by concentrating on the virus and halting its reproduction and spread throughout the body. Virus diseases like the flu, herpes, HIV/AIDS, hepatitis B and C, and other viral infections are frequently treated with antivirals. Depending on the infection type being treated, they can be given orally, topically, or intravenously.
Anti Infective Drugs Market, By Indication
HIV
Pneumonia
Respiratory Infections
Tuberculosis
Others
Based on Indication, the market is segmented into HIV, Pneumonia, Respiratory Infections, Tuberculosis, and Others. Pneumonia is an infection of the lungs that can be brought on by bacteria, viruses, fungi, or other pathogens. Anti-infective medications are used to treat pneumonia. Depending on the underlying cause of the infection, the anti-infective medication used to treat pneumonia is chosen. The initial line of therapy for bacterial pneumonia is antibiotics. They function by eliminating infection-causing germs and lowering lung inflammation. Penicillin, cephalosporins, macrolides, fluoroquinolones, and tetracyclines are a few of the typical antibiotics used to treat bacterial pneumonia.
Antibiotics are frequently used as the first line of treatment for bacterial respiratory infections like streptococcal pharyngitis (strep throat), bacterial sinusitis, and bacterial pneumonia. The particular antibiotic administered will depend on the kind of bacteria that is infected and how susceptible it is to various medications. Penicillin, cephalosporins, macrolides, fluoroquinolones, and tetracyclines are typical antibiotics used to treat bacterial respiratory infections.
Anti Infective Drugs Market, By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Anti-infective medication is primarily distributed via hospital pharmacies. These pharmacies are in charge of obtaining, holding, dispensing, and controlling the stock of medications used to treat infections in the hospital context. Given the high prevalence of infectious disorders among hospitalised patients, anti-infective treatments are among the most often prescribed ones in hospitals.
To ensure proper selection, dose, and administration of anti-infective medications, hospital pharmacies often collaborate closely with doctors, including infectious disease specialists and other healthcare professionals. In addition, they are in charge of keeping an eye on and handling any potential negative drug effects, interactions, and problems with drug resistance.
Anti Infective Drugs Market, By Geography
North America
Europe
Asia Pacific
Rest of The World
On the basis of Geography, the Global Anti Infective Drugs Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The biggest market share was held by North America in 2022. In recent years, a number of reasons have contributed to an increase in the need for anti-infective medications in North America. The rising incidence of infectious diseases, notably bacterial and viral infections, in the area is one of the major contributors to this trend.
The need for anti-infective medications has also been influenced by the ageing population and the rise in chronic illnesses including diabetes, cancer, and HIV/AIDS. The expanding prevalence of infections that are resistant to treatment is another factor influencing the increased demand for anti-infective medications in North America. To treat these infections, new and improved antibiotics and antiviral medications are now required.
Key Players
The "Global Anti Infective Drugs Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Novartis AG, Merck & Co., Inc., Alcon Pharmaceuticals Ltd., Quest Diagnostics Inc., AstraZeneca Plc., Anofi SA, GSK, Gilead Sciences, Novartis AG, and Cipla.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.
Key Developments
In August 2021, Pharmaceutical business Xellia Pharmaceuticals, which specialises in anti-infective medications, increased its Ohio production capacity. They distributed the first anti-infectives produced at the facility to US hospitals.
In April 2021, Pfizer, a large global pharmaceutical and biotechnology company, acquired Amplyx Pharmaceuticals, Inc., a business that creates treatments for crippling and fatal illnesses and added Fosmanogepix, a novel antifungal Phase 2 candidate (APX001), to its anti-infectives portfolio. Pfizer now owns Amplyx's early-stage therapeutic portfolio, which includes antiviral (MAU868) and antifungal (APX2039) medications.
Ace Matrix Analysis
The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.
Market Attractiveness
The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Anti Infective Drugs Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
Porter's Five Forces
The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behaviour of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in the Global Anti Infective Drugs Market, gauge the attractiveness of a certain sector, and assess investment possibilities.
TABLE OF CONTENTS
1 INTRODUCTION OF THE GLOBAL ANTI INFECTIVE DRUGS MARKET
1.1 Market Definition
1.2 Market Segmentation
1.3 Research Timelines
1.4 Assumptions
1.5 Limitations
2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH
2.1 Data Mining
2.2 Data Triangulation
2.3 Bottom-Up Approach
2.4 Top-Down Approach
2.5 Research Flow
2.6 Key Insights from Industry Experts
2.7 Data Sources
3 EXECUTIVE SUMMARY
3.1 Market Overview
3.2 Ecology Mapping
3.3 Absolute Market Opportunity
3.4 Market Attractiveness
3.5 Global Anti Infective Drugs Market Geographical Analysis (CAGR %)
3.6 Global Anti Infective Drugs Market, By Drug Type (USD Billion)
3.7 Global Anti Infective Drugs Market, By Indication (USD Billion)
3.8 Global Anti Infective Drugs Market, By Distribution Channel (USD Billion)
3.9 Future Market Opportunities
3.10 Global Market Split
3.11 Product Life Line
4 GLOBAL ANTI INFECTIVE DRUGS MARKET OUTLOOK
4.1 Global Anti Infective Drugs Evolution
4.2 Drivers
4.2.1 Driver1
4.2.2 Driver 2
4.3 Restraints
4.3.1 Restraint1
4.3.2 Restraint 2
4.4 Opportunities
4.4.1 Opportunity1
4.4.2 Opportunity 2
4.5 Porters Five Force Model
4.6 Value Chain Analysis
4.7 Pricing Analysis
4.8 Macroeconomic Analysis
GLOBAL ANTI INFECTIVE DRUGS MARKET, BY DRUG TYPE
4.9 Overview
4.10 Antibiotics
4.11 Antivirals
4.12 Antifungals
5 GLOBAL ANTI INFECTIVE DRUGS MARKET, BY INDICATION
5.1 Overview
5.2 HIV
5.3 Pneumonia
5.4 Respiratory Infections
5.5 Tuberculosis
5.6 Others
6 GLOBAL ANTI INFECTIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.2 Hospital Pharmacies
6.3 Retail Pharmacies
6.4 Others
7 GLOBAL ANTI INFECTIVE DRUGS MARKET, BY GEOGRAPHY
7.1 Overview
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.2.3 Mexico
7.3 Europe
7.3.1 Germany
7.3.2 U.K.
7.3.3 France
7.3.4 Italy
7.3.5 Spain
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 China
7.4.2 Japan
7.4.3 India
7.4.4 Rest of Asia Pacific
7.5 Latin America
7.5.1 Brazil
7.5.2 Argentina
7.5.3 Rest of Latin America
7.6 Middle-East and Africa
7.6.1 UAE
7.6.2 Saudi Arabia
7.6.3 South Africa
7.6.4 Rest of Middle-East and Africa
8 GLOBAL ANTI INFECTIVE DRUGS MARKET COMPETITIVE LANDSCAPE
